BSTC - バイオスペシフィックス・テクノロジ―ズ (BioSpecifics Technologies Corp)


   BioSpecifics Reports Third Quarter 2020 Financial and Operating Results  2020/11/09 13:00:00 PR Newswire
WILMINGTON, Del., Nov. 9, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) ("BioSpecifics" or the "Company"), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as…
   SHAREHOLDER ALERT: WeissLaw LLP Investigates BioSpecifics Technologies Corp.  2020/11/04 00:41:00 PR Newswire
NEW YORK, Nov. 3, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of BioSpecifics Technologies Corp. ("BSTC" or the "Company") (NASDAQ: BSTC) in connection with the proposed acquisition of the…
   Endo International plc Commences Tender Offer for All Outstanding Shares of BioSpecifics Technologies Corp.  2020/11/02 12:00:00 PR Newswire
DUBLIN, Nov. 2, 2020 /PRNewswire/ -- Endo International plc (Nasdaq: ENDP) ("Endo") today announced that Endo's wholly-owned indirect subsidiary, Beta Acquisition Corp. ("Merger Sub"), has commenced its previously announced tender offer to acquire all of the outstanding shares of common…
   BIOSPECIFICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioSpecifics Technologies Corp. - BSTC  2020/10/26 19:02:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioSpecifics Technologies Corp. (NasdaqGS: BSTC) to Endo International plc (NasdaqGS: ENDP). Under the terms of the proposed transaction, shareholders of BioSpecifics will receive only $88.50 in cash for each share of BioSpecifics that they own. KSF is seeking to determine whether this consideration and the pr
   HC Wainwright Downgrades BioSpecifics Technologies (NASDAQ:BSTC) to Neutral  2020/10/22 04:56:51 Stock Observer
BioSpecifics Technologies (NASDAQ:BSTC) was downgraded by stock analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a note issued to investors on Tuesday, reports. They currently have a $88.50 price target on the biopharmaceutical company’s stock, down from their previous price target of $100.00. HC Wainwright’s target price points to […]